KPRX · Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals has secured $5 million in immediate funding through a private placement structured to provide additional capital through milestone-based warrants. The transaction's structure includes two tranches of warrants with acceleration triggers tied to specific corporate developments: Tranche A-1 warrants accelerate upon a strategic transaction that materially expands the company's commercial opportunity, while Tranche A-2 warrants accelerate upon completion of enrollment in any Phase 3 clinical trial. This creates a potential $19 million in additional funding that becomes available as the company achieves key strategic and clinical milestones. The pricing at $2.543 per share (or equivalent for pre-funded warrants) represents the 'Minimum Price' under Nasdaq rules, and the warrants contain standard anti-dilution protections but no price protection or reset provisions. The company's commitment to file a registration statement within 45 days provides investors with liquidity for the securities, while the cashless exercise provisions for the warrants offer flexibility if the registration statement is not effective. The involvement of Perceptive Advisors and ADAR1 Capital Management as sole investors suggests targeted institutional support for Kiora's clinical-stage retinal disease therapies.